ASRT - Assertio Therapeutics, Inc.
| Previous Close | 1.2400 |
| Open | 1.2500 |
| Bid | 0.5000 x 27000 |
| Ask | 0.0000 x 41800 |
| Day's Range | 1.0100 - 1.2800 |
| 52 Week Range | 1.0100 - 6.0700 |
| Volume | 2,218,686 |
| Avg. Volume | 1,339,610 |
| Market Cap | 84.658M |
| Beta (3Y Monthly) | 2.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0610 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- Benzinga
The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
Biotech stocks continued to languish for a third straight week. Negative broader market sentiment and company-specific weakness weighed down on the sector. Pfenex Inc (NYSE: PFNX ) received FDA approval ...
- Simply Wall St.
How Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Affect Your Portfolio Volatility?
If you own shares in Assertio Therapeutics, Inc. (NASDAQ:ASRT) then it's worth thinking about how it contributes to...
- GlobeNewswire
Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors
Assertio Therapeutics, Inc. (ASRT) announced today that Dr. David Wheadon has been appointed to the Company’s Board of Directors. Dr. Wheadon is a former senior executive of AstraZeneca plc. “David is a globally recognized leader in healthcare and we are thrilled to have him join our Board of Directors,” said Arthur Higgins, President and CEO of Assertio.
- GlobeNewswire
Assertio Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference
LAKE FOREST, Ill., Sept. 26, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the Annual Cantor.
- CNW Group
Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes
TORONTO and HOUSTON , Sept. 24, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced the appointment of Ms. Karen Dawes to the Board of Directors of Medicenna and the voting results from the Company's annual meeting of shareholders held today, September 24, 2019 in Toronto (the "Meeting"). A total of 36.15% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.
- Zacks
ASRT vs. ZTS: Which Stock Is the Better Value Option?
ASRT vs. ZTS: Which Stock Is the Better Value Option?
- Zacks
Top Ranked Value Stocks to Buy for September 9th
Top Ranked Value Stocks to Buy for September 9th
- Simply Wall St.
If You Had Bought Assertio Therapeutics (NASDAQ:ASRT) Stock Three Years Ago, You'd Be Sitting On A 94% Loss, Today
As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a while...
- Zacks
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
ASRT vs. ZTS: Which Stock Is the Better Value Option?
- GlobeNewswire
Assertio Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference
LAKE FOREST, Illinois, Aug. 20, 2019 -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that members of senior management will participate at the 17th Annual Morgan.
- Zacks
Assertio Therapeutics Enters Oversold Territory
Assertio Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Zacks
ASRT vs. PCRX: Which Stock Is the Better Value Option?
ASRT vs. PCRX: Which Stock Is the Better Value Option?
- GuruFocus.com
Assertio Therapeutics Inc (ASRT) Director, President and CEO Arthur J Higgins Bought $77,000 of ...
Director, President and CEO of Assertio Therapeutics Inc (30-Year Financial, Insider Trades) Arthur J Higgins (insider trades) bought 50,000 shares of ASRT on 08/12/2019 at an average price of $1.54 a share. Continue reading...
- GlobeNewswire
Assertio Therapeutics Announces Exchange Offer of $200 Million of its Currently Outstanding 2.50% Convertible Notes Due 2021
“We have worked hard to pay down our senior secured debt and with today’s announcement we have taken a significant step toward addressing our 2021 convertible debt. Pursuant to the Exchange Agreements, Assertio will exchange approximately $200 million aggregate principal amount of Exchanged Notes for a combination of (a) its new 5.00% Convertible Senior Notes due August 15, 2024 (the “New Convertible Notes”), (b) a cash payment plus accrued but unpaid interest on the Exchanged Notes, and (c) an agreed number of shares of Assertio’s common stock. The transactions are subject to customary closing conditions and are expected to close on August 13, 2019. The shares of Assertio’s common stock and the New Convertible Notes will be issued in private placements exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). Assertio will issue approximately $120 million aggregate principal amount of New Convertible Notes, pay an aggregate of approximately $30 million in cash and issue an aggregate of approximately 15.8 million shares of its common stock in the transactions.
Motley FoolAssertio Therapeutics, Inc (ASRT) Q2 2019 Earnings Call Transcript
ASRT earnings call for the period ending June 30, 2019.
- Zacks
Assertio (ASRT) Q2 Earnings Beat Estimates
Assertio (ASRT) delivered earnings and revenue surprises of 8.70% and -2.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Assertio Therapeutics Announces Strong Second-Quarter 2019 Results
-- Reports Total Company GAAP Net Sales of $57.2 million, Total Company Non-GAAP Net Sales of $59.3 million, including Commercialization Agreement Revenues of $31.0 million --.
- Simply Wall St.
Is Assertio Therapeutics (NASDAQ:ASRT) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- Zacks
Assertio (ASRT) Earnings Expected to Grow: Should You Buy?
Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
ASRT or AMRX: Which Is the Better Value Stock Right Now?
ASRT vs. AMRX: Which Stock Is the Better Value Option?
- GlobeNewswire
Assertio Therapeutics to Report Second Quarter 2019 Financial Results After The Close of Markets on Wednesday, August 7, 2019
LAKE FOREST, Ill., July 17, 2019 -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release second quarter 2019 financial results on Wednesday, August 7,.
- Zacks
La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza
The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.
- Insider Monkey
Here’s What Hedge Funds Think About Assertio Therapeutics, Inc. (ASRT)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- Simply Wall St.
Have Insiders Been Buying Assertio Therapeutics, Inc. (NASDAQ:ASRT) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- Markit
See what the IHS Markit Score report has to say about Assertio Therapeutics Inc.
Assertio Therapeutics Inc NASDAQ/NGS:ASRTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for ASRT with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 29. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ASRT are favorable, with net inflows of $2.40 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
